How Did COVID-19 Affect Your Spine Tumor Practice?

<p>How has the COVID-19 pandemic impacted your practice? What changed for you and your care team during social distancing phase? What changed for you and your care team after social distancing requirements lapsed? Join Section on Spine Oncology members John H. Shin, MD, Iliya Laufer, MD and Jacob Buchowski, MD, MS as they discuss their experiences over the past 18 months with moderator Matthew Goodwin, MD, PhD, FACSM.</p> <p><br></p> <p>Disclosures:</p> <p>Buchowski, Jacob M.: Device or Biologic Distribution Group (Physician-Owned Distributorship): Globus Medical (E), K2M (C), Wolters Kluwer Health (A); Fellowship Support: AOSpine North America (E, Paid directly to institution/employer), OMeGA (D, Paid directly to institution/employer).</p> <p>Goodwin, Matthew L.: Consulting: Augmedics (A, Outside 12-Month Requirement), JBJS Classroom (A); Fellowship Support: AOSpine (Salary), NREF (Salary); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement, Paid directly to institution/employer).</p> <p>Laufer, Ilya: Consulting: BrainLab (A), DePuy Synthes (B), Globus (B), Medtronic (C), Spine Wave (B).</p> <p>Shin, John H.: Consulting: Carbofix (None), DePuy (B), Medtronic (A), NuVasive (B).</p> <p>Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+</p>